Given small molecule mimetics may offer increased therapeutic efficacy over their peptide counterparts,25, 26 the use of an ADH‐1 mimetic such as LCRF‐0006 is a rational proposition to enhance tumor delivery of plasma protein‐binding drugs and increase clinical effectiveness. This evidence concerns the gene ADH1A and neoplasm.